AU2003280921B2 - A recombinant protein with cancer suppression action, its encoding gene and use - Google Patents

A recombinant protein with cancer suppression action, its encoding gene and use Download PDF

Info

Publication number
AU2003280921B2
AU2003280921B2 AU2003280921A AU2003280921A AU2003280921B2 AU 2003280921 B2 AU2003280921 B2 AU 2003280921B2 AU 2003280921 A AU2003280921 A AU 2003280921A AU 2003280921 A AU2003280921 A AU 2003280921A AU 2003280921 B2 AU2003280921 B2 AU 2003280921B2
Authority
AU
Australia
Prior art keywords
seq
cancer
protein
amino acid
cpt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2003280921A
Other languages
English (en)
Other versions
AU2003280921A1 (en
Inventor
Bing Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Sunbio Biotech Co Ltd
Original Assignee
Beijing Sunbio Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Sunbio Biotech Co Ltd filed Critical Beijing Sunbio Biotech Co Ltd
Publication of AU2003280921A1 publication Critical patent/AU2003280921A1/en
Assigned to SUN BIOTECH PHARMACEUTICALS (TIANJIN) CO. LTD. reassignment SUN BIOTECH PHARMACEUTICALS (TIANJIN) CO. LTD. Request for Assignment Assignors: Beijing Sunbio Biotech Co., Ltd
Assigned to SUNBIO BIOTECH PHARMACEUTICALS (TIANJIN) CO. LTD. reassignment SUNBIO BIOTECH PHARMACEUTICALS (TIANJIN) CO. LTD. Request for Assignment Assignors: SUN BIOTECH PHARMACEUTICALS (TIANJIN) CO. LTD.
Application granted granted Critical
Publication of AU2003280921B2 publication Critical patent/AU2003280921B2/en
Assigned to BEIJING SUNBIO BIOTECH CO., LTD. reassignment BEIJING SUNBIO BIOTECH CO., LTD. Request for Assignment Assignors: SUNBIO BIOTECH PHARMACEUTICALS (TIANJIN) CO. LTD.
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2003280921A 2003-11-03 2003-11-03 A recombinant protein with cancer suppression action, its encoding gene and use Expired AU2003280921B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2003/000928 WO2005042744A1 (en) 2003-11-03 2003-11-03 A recombinant protein with cancer suppression action, its encoding gene and use

Publications (2)

Publication Number Publication Date
AU2003280921A1 AU2003280921A1 (en) 2005-05-19
AU2003280921B2 true AU2003280921B2 (en) 2007-09-13

Family

ID=34529378

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003280921A Expired AU2003280921B2 (en) 2003-11-03 2003-11-03 A recombinant protein with cancer suppression action, its encoding gene and use

Country Status (11)

Country Link
US (1) US7666989B2 (https=)
EP (1) EP1688498B1 (https=)
JP (1) JP4688678B2 (https=)
CN (1) CN100549175C (https=)
AT (1) ATE501256T1 (https=)
AU (1) AU2003280921B2 (https=)
BR (1) BRPI0318594B8 (https=)
CA (1) CA2544473C (https=)
DE (1) DE60336353D1 (https=)
NZ (1) NZ547274A (https=)
WO (1) WO2005042744A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060241051A1 (en) 2002-12-26 2006-10-26 Chieko Kitada Metastin derivatives and use thereof
AR049938A1 (es) 2004-06-25 2006-09-13 Takeda Pharmaceutical Derivados de metastina y utilizacion de los mismos
US8404643B2 (en) 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
TWI386417B (zh) 2005-12-22 2013-02-21 Takeda Pharmaceutical 轉移抑素衍生物及其用途
TWI404726B (zh) 2006-10-25 2013-08-11 Takeda Pharmaceutical 腫瘤轉移抑制素衍生物及其用途
WO2009131191A1 (ja) * 2008-04-24 2009-10-29 武田薬品工業株式会社 メタスチン誘導体およびその用途
HRP20150664T1 (hr) 2010-12-03 2015-07-31 Adamed Sp. Z O.O. Antikancerogeni fuzijski protein
PL219845B1 (pl) 2011-01-05 2015-07-31 Adamed Spółka Z Ograniczoną Odpowiedzialnością Przeciwnowotworowe białko fuzyjne
PL394618A1 (pl) 2011-04-19 2012-10-22 Adamed Spólka Z Ograniczona Odpowiedzialnoscia Przeciwnowotworowe bialko fuzyjne
CN103534273B (zh) * 2011-09-16 2020-05-12 北京沙东生物技术有限公司 环化变构trail/apo2l及其编码基因与应用
PL397167A1 (pl) 2011-11-28 2013-06-10 Adamed Spólka Z Ograniczona Odpowiedzialnoscia Przeciwnowotworowe bialko fuzyjne
PL223487B1 (pl) 2011-12-28 2016-10-31 Adamed Spółka Z Ograniczoną Odpowiedzialnością Przeciwnowotworowe białko fuzyjne

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6284236B1 (en) * 1995-06-29 2001-09-04 Immunex Corporation Cytokine that induces apoptosis
AU708239B2 (en) * 1995-06-29 1999-07-29 Immunex Corporation Cytokine that induces apoptosis
KR20010019100A (ko) * 1999-08-25 2001-03-15 황규언 인간 유래 세포소멸인자 ｔｒａｉｌ의 결정화에 의한 3차원 구조
US6900185B1 (en) * 2000-04-12 2005-05-31 University Of Iowa Research Foundation Method of inducing tumor cell apoptosis using trail/Apo-2 ligand gene transfer
KR100436089B1 (ko) * 2000-07-06 2004-06-14 설대우 분비성 재조합 트라이머형의 트레일 단백질 생산을 위한 디엔에이 카세트, 테트라사이클린/독시사이클린-유도성아데노-관련 바이러스 벡터, 이 둘의 조합, 및 이들을이용한 유전자 치료
CN1205335C (zh) * 2001-11-30 2005-06-08 中国人民解放军第二军医大学 肿瘤凋亡诱导配体基因、基因表达蛋白及其制备方法

Also Published As

Publication number Publication date
WO2005042744A1 (en) 2005-05-12
EP1688498B1 (en) 2011-03-09
CN100549175C (zh) 2009-10-14
ATE501256T1 (de) 2011-03-15
HK1089788A1 (zh) 2006-12-08
BRPI0318594B1 (pt) 2017-12-26
US20080280821A1 (en) 2008-11-13
DE60336353D1 (de) 2011-04-21
CA2544473C (en) 2013-08-13
EP1688498A4 (en) 2007-06-20
BR0318594A (pt) 2006-10-17
BRPI0318594B8 (pt) 2021-05-25
JP2007536891A (ja) 2007-12-20
CN1860229A (zh) 2006-11-08
NZ547274A (en) 2009-02-28
EP1688498A1 (en) 2006-08-09
AU2003280921A1 (en) 2005-05-19
CA2544473A1 (en) 2005-05-12
US7666989B2 (en) 2010-02-23
JP4688678B2 (ja) 2011-05-25

Similar Documents

Publication Publication Date Title
KR102314231B1 (ko) 전립선 암 치료용 조성물
AU2003280921B2 (en) A recombinant protein with cancer suppression action, its encoding gene and use
JP2008043335A (ja) Ａｐｏ−２リガンド変異体とその使用法
JP2004203890A (ja) マクロファージ炎症蛋白変種
JP7830450B2 (ja) 修飾されたｉｌ－２分子及びその用途
RU2333221C2 (ru) Рекомбинантный белок, обладающий противораковым действием, кодирующий его ген и его применение
KR101185310B1 (ko) 변형된 인간 종양 괴사 인자 수용체-1 폴리펩티드 또는 그의 절편 및 그의 제조방법
JP2000505791A (ja) 肥満症タンパク質類似体化合物およびその製剤
KR101273893B1 (ko) 변형된 인간 종양 괴사 인자 수용체-1 폴리펩티드 또는 그의 절편 및 그의 제조방법
KR100863060B1 (ko) 암 억제 활동을 하는 재조합 단백질, 그 암호화 유전자 및 재조합 단백질을 활성성분으로 포함하는 암치료용 약학적 조성물
ZA200604478B (en) A recombinant protein with cancer suppression action, its encoding gene and uses thereof
MXPA06004932A (en) A recombinant protein with cancer suppression action, its encoding gene and use
CN119874872B (zh) 一种mita铰链区突变多肽及其在自身免疫性疾病中的应用
CN100506275C (zh) 成骨生长肽对红系造血祖细胞的促增殖作用及应用
JP5439007B2 (ja) 血管内皮細胞増殖因子阻害剤及び抗癌剤
HK1089788B (en) A recombinant protein with cancer suppression action, its encoding gene and use
Fiers et al. TNF-Mediated Cytotoxicity: Mechanism and Regulation
AU2011235952A1 (en) APO-2 ligand variants and uses thereof

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: SUN BIOTECH PHARMACEUTICALS (TIANJIN) CO. LTD.

Free format text: FORMER APPLICANT(S): BEIJING SUNBIO BIOTECH CO., LTD

TC Change of applicant's name (sec. 104)

Owner name: SUNBIO BIOTECH PHARMACEUTICALS (TIANJIN) CO. LTD.

Free format text: FORMER NAME: SUN BIOTECH PHARMACEUTICALS (TIANJIN) CO. LTD.

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: BEIJING SUNBIO BIOTECH CO., LTD.

Free format text: FORMER OWNER WAS: SUNBIO BIOTECH PHARMACEUTICALS (TIANJIN) CO. LTD.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired